Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q3 2025 Earnings Call Transcript
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q3 2025 Earnings Call Transcript November 12, 2025Atea Pharmaceuticals, Inc. misses on earnings expectations.
Atea Pharmaceuticals Inc. (AVIR)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Tang Capital Management Kevin C. Tang | 4,814,700 | $17,188,479 | -1% | 0.85% |
| 2. | Renaissance Technologies Jim Simons | 1,188,500 | $4,242,945 | -4% | 0.01% |
| 3. | Two Sigma Advisors John Overdeck And David Siegel | 1,059,700 | $3,783,129 | +34% | 0.01% |
| 4. | Millennium Management Israel Englander | 698,156 | $2,492,417 | +44% | 0% |
| 5. | D E Shaw D. E. Shaw | 464,787 | $1,659,289 | +28% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.36 | 10,000 | $33,614.00 | 476,897 | 2025-01-16 | Filing | |
| $3.19 | 15,000 | $47,884.50 | 466,897 | 2025-01-15 | Filing | |
| $3.36 | 10,000 | $33,614.00 | 476,897 | 2025-01-16 | Filing | |
| $3.19 | 15,000 | $47,884.50 | 466,897 | 2025-01-15 | Filing | |
| $8.57 | 12,000 | $102,795.60 | 23,295 | 2021-12-20 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.85 | 359,606 | $1,023,474.64 | 451,897 | 2024-12-10 | Filing | |
| $4.00 | 1,841 | $7,367.50 | 5,866,025 | 2024-09-19 | Filing | |
| $4.03 | 22,187 | $89,469.08 | 5,867,866 | 2024-09-18 | Filing | |
| $4.05 | 33,941 | $137,318.50 | 5,890,053 | 2024-09-17 | Filing | |
| $3.49 | 17,544 | $61,144.35 | 65,606 | 2024-06-20 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 9,678,996 | $34,554,015 | 0% | |
| 2. | 8,491,202 | $30,313,592 | 0% | |
| 3. | 7,490,000 | $26,739,300 | 23.11% | |
| 4. | 4,227,110 | $15,090,783 | 0% | |
| 5. | 2,485,638 | $8,873,728 | 0.68% |
News See All
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q2 2025 Earnings Call Transcript
Operator: Good afternoon, and welcome to the Atea Pharmaceuticals' Second Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note this event is being recorded.
Atea Pharmaceuticals, Inc. (AVIR): A Bull Case Theory
We came across a bullish thesis on Atea Pharmaceuticals, Inc. (AVIR) on Substack by Turtles Research. In this article, we will summarize the bulls’ thesis on AVIR. Atea Pharmaceuticals, Inc.
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2024 Earnings Call Transcript
Operator: Good afternoon, everybody, and welcome to Atea Pharmaceuticals' fourth quarter 2024 Financial Results and Business Update Conference Call.
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q3 2024 Earnings Call Transcript
Operator: Good afternoon, everyone, and welcome to the Atea Pharmaceuticals Third Quarter 2024 Financial Results and Business Update Conference Call.
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q2 2024 Earnings Call Transcript
Operator: Good afternoon, everyone, and welcome to the Atea Pharmaceuticals Second Quarter 2024 Financial Results and Business Update Conference Call.
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q1 2024 Earnings Call Transcript
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q1 2024 Earnings Call Transcript May 14, 2024Atea Pharmaceuticals, Inc. misses on earnings expectations.
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2023 Earnings Call Transcript
Operator: Good afternoon, everyone, and welcome to the Atea Pharmaceuticals Fourth Quarter 2023 Financial Results and Business Update Conference Call.
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q3 2023 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen. Welcome to the Atea Pharmaceuticals Third Quarter 2023 Financial Results and Business Update Conference Call. [Operator Instructions].
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q2 2023 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen. Welcome to the Atea Pharmaceuticals Second Quarter 2023 Financial Results and Business Update Conference Call.
Hedge Fund Resource Center Billionaire Hedge Funds
